ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 3 of 4 for:    miksad

Pembrolizumab in Refractory Advanced Esophageal Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02971956
Recruitment Status : Recruiting
First Posted : November 23, 2016
Last Update Posted : May 4, 2018
Sponsor:
Collaborator:
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
Peter C. Enzinger, MD, Dana-Farber Cancer Institute

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Recruiting
  Estimated Primary Completion Date : June 2020
  Estimated Study Completion Date : June 2024